Skip to contentI
Integra Lifesciences Holdings Corp
I
IARTIntegra Lifesciences Holdings Corp Q3 2021 · 10-Q
Revenue$386.86M$386.86M+4.5% vs Q3 2020 Net Income$43.23M$43.23M+33.7% vs Q3 2020 EPS Diluted$0.51$0.51+34.2% vs Q3 2020 Operating Income$56,439,000−1.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$75,493,000+20.0% Margins · derivedOperating margin14.6%−1.0 pt vs Q3 2020
Net margin11.2%+2.4 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end